OCM™ was significantly better at halting proliferation of MRSA and PA

OCM公司™在阻止MRSA和PA增殖方面明显更好

OCM™ recorded the lowest bacterial counts of any treatment arm

OCM公司™记录了所有治疗组的最低细菌计数

OCM™ alone and OCM™ plus Omeza® Skin Protectant showed significantly faster formation of new tissue in MRSA-infected wounds than any other treatment

OCM公司™单独和OCM™plus Omeza®皮肤保护剂在MRSA感染的伤口中显示出比任何其他治疗方法更快的新组织形成

SARASOTA, Fla., Dec. 8, 2023 /PRNewswire/ -- Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today presented in vivo data showing that OCM™ alone significantly reduced methicillin-resistant staphylococcus (MRSA) aureus and pseudomonas aeruginosa (PA) bacterial counts and accelerated the formation of new tissue in MRSA-infected wounds, outperforming a comparator treatment and a control group..

佛罗里达州萨拉索塔，2023年12月8日/PRNewswire/--Omeza®，一家再生皮肤护理公司，开发用于治疗慢性伤口的海洋疗法，今天提供的体内数据显示，OCM™单独使用可显着降低耐甲氧西林金黄色葡萄球菌（MRSA）和铜绿假单胞菌（PA）的细菌计数，并加速MRSA感染伤口中新组织的形成，优于对照组和对照组。。

Results of the in vivo data conducted in a porcine model—the most similar to human skin in both morphological structure and immunohistochemical properties1—are being presented at the Innovations in Wound Healing conference Dec. 7 – 10.

在猪模型中进行的体内数据的结果-在形态结构和免疫组织化学特性方面与人类皮肤最相似1-将在12月7日至10日的伤口愈合创新会议上发表。

'Infections are a leading cause of stalled wounds, with bacteria in biofilms estimated to be involved in more than 60 % of chronic wounds2,' said Suzanne Bakewell, Ph.D., Chief Scientific Officer at Omeza®. 'Limiting bacterial growth is a critical therapeutic aim in treating advanced wounds, but complicating factors often prevent success.

“感染是伤口停滞的主要原因，生物膜中的细菌估计涉及60多种 %Omeza®首席科学官SuzanneBakewell博士说，慢性伤口2限制细菌生长是治疗晚期伤口的关键治疗目标，但复杂因素通常会阻止成功。

OCM™ does not confer these complications, such as antibiotic resistance, cytotoxicity, or viral transmission.'.

OCM公司™不会带来这些并发症，例如抗生素耐药性，细胞毒性或病毒传播。”。

The current study was designed to evaluate the antimicrobial and wound-healing effects of OCM™ and Omeza® Skin Protectant against a comparator and a control in a porcine wound model. OCM™ is a novel, propriety, drug/device comprising cold-water fish peptides and other pharmaceutical-grade ingredients that create an absorbable matrix which integrates into the wound bed to support the synthesis of new tissue..

目前的研究旨在评估OCM的抗菌和伤口愈合效果™和Omeza®皮肤保护剂对抗猪伤口模型中的比较器和对照。OCM公司™是一种新型，合适的药物/装置，包含冷水鱼肽和其他药物级成分，可产生可吸收基质，整合到伤口床中以支持新组织的合成。。

Study Design

研究设计

In the study, wounds were inoculated with MRSA and PA, then treated with either OCM™ alone; OCM™ plus Omeza® Skin Protectant; a silver dressing (positive control); or debridement only (negative control). Wounds in all groups were debrided, treated (except negative control), covered with polyurethane dressings, and retreated on days 4 and 8.

在这项研究中，伤口接种了MRSA和PA，然后用任何一种OCM治疗™独自一人；OCM公司™加上Omeza®皮肤保护剂；银敷料（阳性对照）；或仅清创术（阴性对照）。所有组的伤口均清创，治疗（阴性对照除外），用聚氨酯敷料覆盖，并在第4天和第8天复治。

All wounds were assessed on Days 4, 8, and 12 for bacterial counts, among other measures..

在第4,8和12天评估所有伤口的细菌计数以及其他措施。。

Study Results

研究结果

Results of the study showed the following:

研究结果表明：

OCM™ alone was significantly better at halting proliferation in both MRSA USA300- and PA27312-infected wounds compared with baseline before and after debridement and compared with all other treatment groups.

OCM公司™与清创前后的基线相比，单独使用MRSA USA300和PA27312感染的伤口在阻止增殖方面明显更好，并且与所有其他治疗组相比。

Among all treatments at all time points, the lowest MRSA USA300 and PA27312 counts occurred on Day 12 in wounds treated with OCM™ alone.

在所有时间点的所有治疗中，用OCM治疗的伤口在第12天出现最低的MRSA USA300和PA27312计数™独自一人。

OCM™ alone and OCM™ plus Omeza® Skin Protectant showed significantly faster formation of new tissue in MRSA USA300-infected wounds compared to the silver dressing and the control group.

OCM公司™单独和OCM™与银敷料和对照组相比，plus Omeza®皮肤保护剂在MRSA USA300感染的伤口中显示出明显更快的新组织形成。

'These in vivo data constitute an important finding that may have significant clinical implications for the management of many wound etiologies, such as burns, diabetic foot ulcers, venous leg ulcers, and pressure ulcers,' said Dr. Windy Cole, DPM, adjunct professor and Director of Wound Care Research at Kent State University College of Podiatric Medicine..

肯特州立大学足病医学院（Kent State University College of Fodiatric Medicine）副教授兼伤口护理研究主任温迪·科尔（Windy Cole）博士（Dr.Windy Cole）说：“这些体内数据构成了一个重要发现，可能对许多伤口病因的治疗具有重要的临床意义，例如烧伤，糖尿病足溃疡，静脉性腿部溃疡和压疮。”。。

'In recent years, researchers have amassed compelling evidence of multiple pathways through which marine-derived ingredients exert their effects on the immune system and wound healing at both the cellular and molecular levels, including their ability to reduce inflammation and increase metabolic activity of fibroblasts and keratinocytes3-6, which are critical for protecting against microbial invasion,' said Dr.

“近年来，研究人员积累了令人信服的证据，证明海洋衍生成分通过多种途径在细胞和分子水平上对免疫系统和伤口愈合产生影响，包括减少炎症和增加成纤维细胞和角质形成细胞代谢活性的能力3-6，这对防止微生物入侵至关重要。

Cole..

科尔。。

'The in vivo study of OCM™ supports these foundational studies and demonstrates that a specific therapy—OCM™—confers these antimicrobial benefits in porcine wounds, and the potential is likely in human wounds, as well,' Dr. Cole said.

“OCM的体内研究™支持这些基础研究，并证明特定疗法OCM™—科尔博士说，这些抗菌药物对猪的伤口有好处，对人体伤口也有潜在的作用。

Omeza® is currently evaluating its platform in three clinical studies among patients with diabetic foot ulcers, venous leg ulcers, and chronic wounds of multiple wound etiologies in a real-world setting. Among the endpoints are safety; change in percent area reduction; ability to move wounds from chronicity to a healing trajectory in a 4-week period; and time to complete wound closure..

Omeza®目前正在三项临床研究中评估其平台，这些研究针对糖尿病足溃疡，静脉性腿部溃疡和现实环境中多种伤口病因的慢性伤口患者。终点之一是安全性；面积减少百分比的变化；能够在4周内将伤口从慢性转移到愈合轨迹；以及完成伤口闭合的时间。。

References:

参考文献：

1https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547536/#:~:text=Porcine%20skin%20is%20often%20used,properties%20(15%E2%80%9318)2https://www.frontiersin.org/articles/10.3389/fimmu.2021.648554/full3https://web.archive.org/web/20220425210925id_/https://onlinelibrary.wiley.com/doi/pdf/10.1111/exd.145064https://web.archive.org/web/20220425210925id_/https://onlinelibrary.wiley.com/doi/pdf/10.1111/exd.145065https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117694/#B98-marinedrugs-16-002566https://www.hmpgloballearningnetwork.com/site/wmp/article/nutrition-411-omega-3-fatty-acids-and-wound-healing .

1https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9547536/#:~:text=Porcine%20skin%20is%20often%20used,properties%20(15%E2%80%9318)2https://www.frontiersin.org/articles/10.3389/fimmu.2021.648554/full3https://web.archive.org/web/20220425210925id_/https://onlinelibrary.wiley.com/doi/pdf/10.1111/exd.145064https://web.archive.org/web/20220425210925id_/https://onlinelibrary.wiley.com/doi/pdf/10.1111/exd.145065https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6117694/#b98-marinedrugs-16-002566https://www.hmpgloballearningnetwork.com/site/wmp/article/nutrition-411-omega-3-fatty-acids-and-wound-healing .

About OMEZA®

关于OMEZA®

Omeza® is a commercial-stage regenerative skin and wound-care company that develops marine-based products comprising cold water fish peptides and other pharmaceutical-grade ingredients. Founded in 2014, the company currently markets three products (OCM™, Omeza® Lidocaine Lavage, and Omeza®Skin Protectant) designed to reduce inflammation, increase skin proliferation, and support skin remodeling in adults with a range of chronic, non-healing wounds.

Omeza®是一家商业级再生皮肤和伤口护理公司，开发包含冷水鱼肽和其他药物级成分的海洋产品。该公司成立于2014年，目前销售三种产品（OCM™,Omeza®利多卡因灌洗液和Omeza®皮肤保护剂）旨在减轻炎症，增加皮肤增殖，并支持患有一系列慢性不愈合伤口的成年人的皮肤重塑。

Three clinical trials underway are evaluating the Omeza® platform in diabetic foot ulcers, venous leg ulcers, and wounds of multiple etiologies in the real-world setting. The company is headquartered in Sarasota, Florida, and has research, manufacturing, and analytical facilities located throughout Florida..

正在进行的三项临床试验正在评估Omeza®平台在现实环境中治疗糖尿病足溃疡，静脉性腿部溃疡和多种病因的伤口。该公司总部位于佛罗里达州萨拉索塔，在佛罗里达州拥有研究、制造和分析设施。。

Media Contacts:

媒体联系人：

Becky Levine[email protected](888) 886-6392

贝基·莱文[受电子邮件保护]（888）886-6392

Bernadette Cupit[email protected]908-334-4554

Bernadette Cupit[受电子邮件保护]908-334-4554

SOURCE Omeza LLC

SOURCE Omeza有限责任公司